Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 257

1.

Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.

Peura P, Martikainen J, Soini E, Hallinen T, Niskanen L.

Curr Med Res Opin. 2008 Jun;24(6):1823-32. doi: 10.1185/03007990802144705. Epub 2008 May 15.

PMID:
18485270
2.

Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain.

Barrios V, Lobos JM, Serrano A, Brosa M, Capel M, Alvarez Sanz C.

J Med Econ. 2012;15 Suppl 1:45-54. doi: 10.3111/13696998.2012.726674. Epub 2012 Sep 12.

PMID:
22954062
4.

Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.

Ohsfeldt RL, Gandhi SK, Fox KM, Stacy TA, McKenney JM.

Am J Manag Care. 2006 Nov;12(15 Suppl):S412-23.

5.

Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.

Montouchet C, Ruff L, Balu S.

J Med Econ. 2013 Jul;16(7):907-16. doi: 10.3111/13696998.2013.801350. Epub 2013 May 23.

PMID:
23641809
6.

Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.

Costa-Scharplatz M, Ramanathan K, Frial T, Beamer B, Gandhi S.

Clin Ther. 2008 Jul;30(7):1345-57.

PMID:
18691996
8.

Impact of restricted reimbursement on the use of statins in Finland: a register-based study.

Martikainen JE, Saastamoinen LK, Korhonen MJ, Enlund H, Helin-Salmivaara A.

Med Care. 2010 Sep;48(9):761-6. doi: 10.1097/MLR.0b013e3181e41bcb.

PMID:
20706164
9.

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.

10.

Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals.

Hirsch M, O'donnell J, Olsson A.

Int J Cardiol. 2005 Oct 10;104(3):251-6.

PMID:
16186052
11.
12.

Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial.

Ohsfeldt RL, Olsson AG, Jensen MM, Gandhi SK, Paulsson T.

J Med Econ. 2012;15(1):125-33. doi: 10.3111/13696998.2011.627073. Epub 2011 Nov 4.

PMID:
22050473
13.

Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal.

Pinto CG, Carrageta MO, Miguel LS.

Value Health. 2008 Mar-Apr;11(2):154-9. doi: 10.1111/j.1524-4733.2007.00224.x.

14.

Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?

Ara R, Pandor A, Stevens J, Rafia R, Ward SE, Rees A, Durrington PN, Reynolds TM, Wierzbicki AS, Stevenson M.

Eur J Prev Cardiol. 2012 Jun;19(3):474-83. doi: 10.1177/1741826711406616. Epub 2011 Apr 1.

PMID:
21460076
15.

[Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].

Araujo DV, Ribeiro de Souza CP, Bahia LR, Rey HC, Dos Santos Junior B, Tura BR, Berwanger O, Buehler AM, Silva MT.

Value Health. 2011 Jul-Aug;14(5 Suppl 1):S29-32. doi: 10.1016/j.jval.2011.05.024. Portuguese.

16.

Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.

Ribeiro RA, Duncan BB, Ziegelmann PK, Stella SF, Vieira JL, Restelatto LM, Polanczyk CA.

Arq Bras Cardiol. 2015 Jan;104(1):32-44. doi: 10.5935/abc.20140173. Epub 2014 Nov 18. English, Portuguese. Erratum in: Arq Bras Cardiol. 2015 Oct;105(4):445.

17.

Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications.

Ohsfeldt RL, Gandhi SK, Fox KM, McKenney JM.

Value Health. 2008 Dec;11(7):1061-9. doi: 10.1111/j.1524-4733.2008.00354.x. Epub 2008 May 16.

18.

Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.

Lindgren P, Graff J, Olsson AG, Pedersen TJ, J├Ânsson B; IDEAL Trial Investigators.

Eur Heart J. 2007 Jun;28(12):1448-53. Epub 2007 Mar 19.

PMID:
17371782
19.

The value of atorvastatin over the product life cycle in the United States.

Grabner M, Johnson W, Abdulhalim AM, Kuznik A, Mullins CD.

Clin Ther. 2011 Oct;33(10):1433-43. doi: 10.1016/j.clinthera.2011.08.014. Epub 2011 Sep 28.

PMID:
21955936
20.

Supplemental Content

Support Center